AERI - Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales
- Aerie Pharma ( NASDAQ: AERI ) is trading 14% higher after it reported Q2 result that beat estimates and 2022 net product revenues guidance that were in line with estimates.
- The company sees total glaucoma franchise net product revenues between $130M to $140M vs $136.90M consensus.
- It posted loss per share of -$0.32, which beat estimates by $0.23, while revenue rose 22.4% Y/Y to $33.3M.
- The company also announced that its Investigational New Drug Application submission for AR-14034 in wet age-related macular degeneration is expected in the fourth quarter of 2022.
- The company had Cash of $184.4M as of June 30.
For further details see:
Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales